Volume 17, Number 4—April 2011
CME ACTIVITY - Research
H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.
Release date: March 23, 2011; Expiration date: March 23, 2012
Upon completion of this activity, participants will be able to:
- Distinguish clinical characteristics associated with treatment-resistant pandemic (H1N1) 2009
- Analyze outcomes of patients infected with treatment-resistant pandemic (H1N1) 2009
- Identify the rate of H275Y mutation development among patients with pandemic (H1N1) 2009 infection in the current study
- Evaluate the virology of treatment-resistant pandemic (H1N1) 2009
Medscape CME Editor
Karen L. Foster, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.
Medscape CME Author
Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.
Disclosures: Christian Renaud, MD, MSc; Alexandre A. Boudreault; Jane Kuypers, PhD; Kathryn H. Lofy, MD; and Lawrence Corey, MD, have disclosed no relevant financial relationships. Michael J. Boeckh, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Adamas, GlaxoSmithKline, and Roche; served as an advisor or consultant for Baxter HealthCare Pharmaceuticals and Roche/Genentech, Inc. Janet A. Englund, MD, has disclosed the following relevant financial relationships: received grants for clinical research from Adamas, ADMA, Chimerix, MedImmune Inc., and Novartis Pharmaceuticals Corporation; served as an advisor to US Attorney General, District of Alaska.
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: September 01, 2011
- Page last updated: September 01, 2011
- Page last reviewed: September 01, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)